companydata.dkLIPLASOME PHARMA ApS: Financial statements 2012
CVR: 29428514
LIPLASOME PHARMA ApS (CVR 29428514) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK -850,000 and a net result of DKK -3,002,000. Equity amounted to DKK 19,741,000. The solvency ratio was 95.9%. The company had 2 employees in the financial year.
- Gross Profit
- -850,000 kr.
- Profit/Loss
- -3,002,000 kr.
- Equity
- 19,741,000 kr.
- Total Assets
- 20,587,000 kr.
- Employees
- 2
How creditworthy is LIPLASOME PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2012
As of August 24, 2012, Hans-Henrik Horsted Eriksen has joined the board of directors of LIPLASOME PHARMA ApS.
As of August 24, 2012, John Riis Mortensen has joined the board of directors of LIPLASOME PHARMA ApS.
As of August 24, 2012, Duncan Moore has joined the board of directors of LIPLASOME PHARMA ApS.
As of August 24, 2012, Torben Brøgger-Mikkelsen has left the board of directors of LIPLASOME PHARMA ApS.
As of August 24, 2012, Holger Bagger-Sørensen has left the board of directors of LIPLASOME PHARMA ApS.
As of August 24, 2012, Torben Vilsgaard has left the board of directors of LIPLASOME PHARMA ApS.
As of August 24, 2012, Steen Bagger-Sørensen has left the board of directors of LIPLASOME PHARMA ApS.
As of August 24, 2012, Claus Bagger-Sørensen has left the board of directors of LIPLASOME PHARMA ApS.
As of August 24, 2012, Hans-Henrik Horsted Eriksen is registered as adm. dir. of LIPLASOME PHARMA ApS.
About LIPLASOME PHARMA ApS
LIPLASOME PHARMA ApS is a Danish company of the type Anpartsselskab based in Vejle, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Hans-Henrik Horsted Eriksen. The company is owned by BAGGER-SØRENSEN & CO. A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -28,000 and a net result of DKK 62,000 compared with DKK -36,000 the year before. Equity amounted to DKK 2,377,000.